Cargando…
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864649/ https://www.ncbi.nlm.nih.gov/pubmed/34965297 http://dx.doi.org/10.1182/bloodadvances.2019001205 |